Neurol Neuroimmunol Neuroinflamm 2022 Jul 21;9(4). Epub 2022 Jun 21.
From the Neuromuscular Diseases Unit (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.C.-V.), Department of Neurology, Hospital de la Santa Creu i Sant Pau, "Departament de Medicina," Universitat Autònoma de Barcelona; Neuromuscular Diseases Lab (D.R.-L., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., A.V.-C., I.I., E.G., E.C.-V.), Institut de Recerca Hospital de la Santa Creu i Sant Pau (IIB-Sant Pau), Barcelona; Centro de Investigación Biomédica en Red de Enfermedades Raras (CIBERER) (D.R.-L., F.P.-J., R.R.-G., J.T.-S., L.Q., M.O., R.Á.-V., M.C.-Á., Á.C., I.I., E.G., E.C.-V.), Valencia; Unidad de Enfermedades Infecciosas (J.L.-C., P.D.), Servicio de Medicina Interna, Hospital de la Santa Creu i Sant Pau; and Department of Immunology (E.M., E.L.-P.), Hospital de la Santa Creu i Sant Pau, Biomedical Research Institute Sant Pau (IIB Sant Pau), Universitat Autònoma de Barcelona, Spain.
Background And Objectives: Evidence regarding the safety and efficacy of messenger RNA (mRNA) vaccines in patients with myasthenia gravis (MG) after immunosuppressive therapies is scarce. Our aim is to determine whether the mRNA-1273 vaccine is safe and able to induce humoral and cellular responses in patients with MG.
Methods: We performed an observational, longitudinal, prospective study including 100 patients with MG of a referral center for MG in our country, conducted from April 2021 to November 2021 during the vaccination campaign. Read More